Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

InterMune, Inc.

http://www.intermune.com

Latest From InterMune, Inc.

Otsuka Counts The Cost Of Alzheimer’s Agitation Fail

The group will take a $770m impairment charge thanks to the Phase III failure of AVP-786 – but further trials continue.

Clinical Trials Neurology

EU’s Innovative Drug Approval Tally Shows Sharp Decline

The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus.

Europe Approvals

The ‘Haves And Have-Nots’ Are Becoming Clearer In Cell And Gene Therapy

2023 saw a number of gene therapy companies go to the wall, but those that can combine clinical significance and commercial success can build sustainable businesses.

Gene Therapy Regenerative Medicine

Reviva’s First Phase III Schizophrenia Readout Rivals Karuna’s Stellar KarXT

Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.

Clinical Trials Strategy
See All

Company Information

UsernamePublicRestriction

Register